Figure 2
Risk of progression to myeloma or related disorder in 273 patients with SMM. Risk of progression of SMM to active myeloma using serum κ to λ FLC ratio of less than 0.125 (< 1:8) or more than 8 (top curve) versus 0.125 to 8 (bottom curve).
Risk of progression to myeloma or related disorder in 273 patients with SMM. Risk of progression of SMM to active myeloma using serum κ to λ FLC ratio of less than 0.125 (< 1:8) or more than 8 (top curve) versus 0.125 to 8 (bottom curve).
